Related Experiment Video
Updated: May 17, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?
Insights
Vascular calcification is a progressive issue in chronic kidney disease (CKD) linked to cardiovascular disease. Early intervention and careful selection of phosphate binders are crucial for managing CKD patients.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Mineral and Bone Disorders
Background:
- Chronic kidney disease (CKD) is associated with increased cardiovascular disease (CVD) mortality.
- Vascular calcification is a significant contributor to the poor health status and decreased survival in CKD patients.
- Non-traditional risk factors like hyperphosphatemia and elevated calcium-phosphate product are implicated in vascular calcification.
Discussion:
- The use of calcium-containing phosphate binders is under scrutiny for its role in vascular calcification.
- Elevated parathyroid hormone levels are implicated in the progression of vascular calcification.
- A proactive and comprehensive strategy is necessary to combat vascular calcification in CKD.
Key Insights:
- Early intervention in CKD is vital to mitigate vascular calcification.
- The choice of phosphate binder is critical, particularly when vascular calcification is present.
- Understanding the interplay of mineral metabolism and vascular health is key in CKD management.
Outlook:
- Further research into novel phosphate binders and therapeutic strategies is warranted.
- Long-term studies are needed to evaluate the impact of different phosphate binders on vascular calcification progression.
- Integrating vascular health monitoring into routine CKD care may improve patient outcomes.
Abstract:
It has been more than 2000 years since Hippocrates described renal disease and observed its progressive nature. Decreased survival and deteriorated health status of these patients' being is attributed to cardiovascular disease. There is increasing interest regarding the impact of non-traditional risk factors, including hyperphosphatemia, elevated calcium-phosphate (CaxPO(4)) product, elevated parathyroid hormone levels and extensive use of calcium-containing phosphate binders on vascular calcification. There is a mounting body of evidence implying that a holistic and methodic approach should clearly suggest starting the battle against vascular calcification early in the course of chronic kidney disease. Type of phosphate binder used should be carefully selected, especially in the presence of vascular calcification.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease I: Introduction
Acute Kidney Injury VI: Nursing Management
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
